An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of PDNO (Nitrosooxypropanol) Infusion in COVID-19 Patients With Acute Pulmonary Hypertension
Latest Information Update: 12 Sep 2023
Price :
$35 *
At a glance
- Drugs Nitrosooxypropanol (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors Attgeno
- 31 Jul 2023 Status changed from discontinued to withdrawn prior to enrolment.
- 31 May 2023 Status changed from recruiting to discontinued.
- 17 Jan 2023 Planned End Date changed from 15 Aug 2022 to 31 May 2023.